Treatment of nonalcoholic fatty liver disease: role of AMPK
Top Cited Papers
Open Access
- 1 October 2016
- journal article
- review article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 311 (4) , E730-E740
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide epidemic and an important risk factor for the development of insulin resistance, type 2 diabetes, nonalcoholic steatohepatitis (NASH), and hepatic cellular carcinoma (HCC). Despite the prevalence of NAFLD, lifestyle interventions involving exercise and weight loss are the only accepted treatments for this disease. Over the last decade, numerous experimental compounds have been shown to improve NAFLD in preclinical animal models, and many of these therapeutics have been shown to increase the activity of the cellular energy sensor AMP-activated protein kinase (AMPK). Because AMPK activity is reduced by inflammation, obesity, and diabetes, increasing AMPK activity has been viewed as a viable therapeutic strategy to improve NAFLD. In this review, we propose three primary mechanisms by which AMPK activation may improve NAFLD. In addition, we examine the mechanisms by which AMPK is activated. Finally, we identify 27 studies that have used AMPK activators to reduce NAFLD. Future considerations for studies examining the relationship between AMPK and NAFLD are highlighted.Keywords
This publication has 139 references indexed in Scilit:
- AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net PhosphorylationCell Metabolism, 2013
- Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver DiseaseCell Metabolism, 2012
- AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant MiceCell Metabolism, 2011
- Structure of mammalian AMPK and its regulation by ADPNature, 2011
- Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humansBiochemical and Biophysical Research Communications, 2011
- Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK ActivationCell Metabolism, 2010
- Effect of 6‐Month Calorie Restriction and Exercise on Serum and Liver Lipids and Markers of Liver FunctionObesity, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistanceProceedings of the National Academy of Sciences, 2007
- Structural basis for AMP binding to mammalian AMP-activated protein kinaseNature, 2007